CRISPR Therapeutics Trading Halted Today; FDA Advisory Committee To Review Biologics License Application (BLA) For Exagamglogene Autotemcel (exa-cel) In Sickle Cell Disease
Portfolio Pulse from Benzinga Newsdesk
Trading of CRISPR Therapeutics (CRSP) has been halted today as the FDA Advisory Committee is set to review the Biologics License Application (BLA) for Exagamglogene Autotemcel (exa-cel) in Sickle Cell Disease.
October 31, 2023 | 11:15 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
CRISPR Therapeutics' stock trading has been halted due to an upcoming FDA review of its Biologics License Application for a Sickle Cell Disease treatment.
The halt in trading is a significant event for CRISPR Therapeutics. The outcome of the FDA review could have a major impact on the company's future, as approval of the BLA would allow the company to market and sell its Sickle Cell Disease treatment. This could potentially lead to significant revenue growth. However, the uncertainty surrounding the review outcome makes the short-term impact on the stock price neutral.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100